drugset
drugset / Trial / NCT03505190

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RO7062931 in Healthy Chinese Volunteers.

NCT03505190 ↗

Phase 1 Completed 41 enrolled Hoffmann-La Roche
RandomizedSequentialDouble-blindTreatment

Summary

This randomized study will evaluate the safety, tolerability and pharmacokinetics of single ascending subcutaneously administered doses of RO7062931 in healthy volunteers.

Timeline

Start
2018-05-03
Primary completion
2019-07-05
Completion
2019-07-05

Drugs

EvaluationDrugModalityDoseRoute
Subject RO7062931 Antisense oligonucleotide 0.3 mg/kg Subcutaneous
Subject RO7062931 Antisense oligonucleotide 1 mg/kg Subcutaneous
Subject RO7062931 Antisense oligonucleotide 2 mg/kg Subcutaneous
Subject RO7062931 Antisense oligonucleotide 3 mg/kg Subcutaneous
Subject RO7062931 Antisense oligonucleotide 4 mg/kg Subcutaneous

Indications

No indication recorded.